Compare GSK plc (GSK) vs Marriott International Inc (MAR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Marriott International Inc — how do they compare? GSK plc trades at $46.52 (market cap $91.88B), while Marriott International Inc trades at $366.01 (market cap $94.16B). The key difference: GSK plc and Marriott International Inc are close in size by market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Marriott International Inc for 164 Days on average.
| GSK | MAR | |
|---|---|---|
Market Cap | $91.88B | $94.16B |
Volume | 7,730,529 | 996,176 |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $402.54 |
52-Week Low | $43.24 | $259.04 |
Typical Hold Time | 93 Days | 164 Days |
Enterprise Value | $111.88B | $111.47B |
Dividend Yield | 3.9% | 0.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
Marriott International (MAR) trades at $365.88, up 2.63% with strong technical momentum and bullish moving averages. The company shows solid revenue growth to $26.19B in 2025 and consistent earnings beats, though valuation ratios remain elevated with a P/E of 37.38. Recent developments include strategic technology partnerships and dividend declarations, while institutional activity shows mixed positioning adjustments.
Outlook remains positive with analyst consensus target of $386.71 offering 5.7% upside potential. Key opportunities include travel recovery momentum and operational efficiency gains, while risks center on high debt levels (debt-to-asset ratio of 58.83%) and potential economic sensitivity. The stock presents a balanced risk-reward profile with moderate growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →
